QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-buy-on-boston-scientific-raises-price-target-to-130

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target fro...

 wells-fargo-maintains-overweight-on-boston-scientific-raises-price-target-to-125

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Overweight and raises the price target fro...

 morgan-stanley-maintains-overweight-on-boston-scientific-raises-price-target-to-130

Morgan Stanley analyst Patrick Wood maintains Boston Scientific (NYSE:BSX) with a Overweight and raises the price target fro...

 tech-stocks-drop-netflix-sinks-10-on-worst-day-since-2022-whats-moving-markets-wednesday

Risk sentiment deteriorated sharply on Wednesday as a wave of disappointing earnings guidance and escalating U.S.-China trade t...

 btig-reiterates-buy-on-boston-scientific-maintains-132-price-target

BTIG analyst Marie Thibault reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $132 price target.

 boston-scientific-gains-momentum-as-growth-broadens-goldman-sachs-says

Goldman Sachs analyst David Roman reiterated a Buy rating and $120 price target for Boston Scientific after strong Q3 results a...

 boston-scientific-jumps-on-strong-guidance-heart-devices-fuel-topline-growth

Boston Scientific Q3 revenue hit $5.07 billion, beating forecasts. The company raised its full-year guidance based on strong se...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION